Article Text

Download PDFPDF
EP852 Ovarian cancer recurrence post ultraradical primary debulking. Role of HIPEC
  1. E Geramani,
  2. A Fotiou,
  3. V Psomiadou,
  4. M Drakou,
  5. A Douligeris,
  6. S Lekka,
  7. C Iavazzo and
  8. G Vorgias
  1. Gynecological Department, Metaxa Cancer Hospital, Pireus, Greece


Introduction/Background Ovarian epithelial cancer presents in advanced stages (III/IV) and is typically managed by combination of cytoreductive plus adjuvant chemotherapy. Cytoreduction increases the postoperative sensitivity of adjuvant chemotherapy and longer free-disease interval.

Methodology Our case describes an aggressive surgical primary cytoreductive surgery including total abdominal hysterectomy, bilateral salpingo-oophorectomy, appendicectomy, total omentectomy, extended right colectomy, partial pelvic peritonectomy, diaphragm peritonectomy, splenectomy partial pancreatectomy and resection of round ligament of liver (CC=0) followed by 6 cycles of adjuvant chemotherapy carbo/taxol. After 12 months recurrent disease was detected by increased levels of tumor markers and PET scan showing distal metastasis (segment II of liver, enlargement of paraortic lymph nodes).

Results The patient had a secondary complete cytoreductive surgery followed by HIPEC using cisplatin. After three months of the second debulking operation our patient performed an other PET scan that showed off reccurence of disease in multiple peritoneal sites.

Conclusion Concluding, HIPEC has promising role in ovarian cancer recurrence. However early relapse can be found even after maximum secondary cytoreduction plus HIPEC.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.